Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Safety profile differences between salbutamol and levosalbutamol: Results from the FDA Adverse Event Reporting System

Wenzhong Peng¹, Jia Chen², Ruoxi He¹, Yongjun Tang¹, Juan Jiang¹, Ling Ouyang³, Dandan Zhao³, Ying Li¹

¹Department of Respiratory Medicine, National Key Clinical Specialty, Xiangya Hospital, Central South University, Hunan 410078, China; ²The Second Department of Respiratory Medicine, Third Peopleâ€™s Hospital of Pingxiang City, Jiangxi Province, 3Joincare Pharmaceutical Group Industry Co. Ltd, Shenzhen, China.

For correspondence:- Ying Li Email: liying971@163.com

Accepted: 29 March 2023 Published: 29 April 2023

Citation: Peng W, Chen J, He R, Tang Y, Jiang J, Ouyang L, et al. Safety profile differences between salbutamol and levosalbutamol: Results from the FDA Adverse Event Reporting System. Trop J Pharm Res 2023; 22(4):909-915 doi: 10.4314/tjpr.v22i4.26

© 2023 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To examine the safety profiles of salbutamol and levosalbutamol reported in the Food and Drug Administration Adverse Event Reporting System (FAERS) database.

Methods: Retrospective pharmacovigilance disproportionality analysis for drug-related ADRs reported in the FAERS database was performed from October 1, 2003 to March 31, 2020. The proportion of report ratio (PRR), proportional reporting ratio (PRR), and reporting odds ratio (ROR) were calculated and used for the determination of safety signals. The definition was based on system organ class (SOCs) and Standardized Medical Dictionary for Regulatory Activities Queries (SMQ) by the Medical Dictionary for Regulatory Activities (MedDRA).

Results: A total of 83,166 and 3,133 adverse event reports were identified for albuterol and levalbuterol, respectively, and were linked mainly with 12 SOCs, i.e., cardiac, vascular disorders, respiratory, thoracic, mediastinal disorders, and immune system disorders. The largest ROR among the 20 most frequent SMQs was asthma/bronchospasm for reports both in salbutamol group (ROR: 13.585, 95% CI: 13.254, 13.923) and levosalbutamol group (ROR: 16.225, 95% CI: 14.575, 18.063).

Conclusion: Data mining of the FAERS may be considered a useful approach for identifying salbutamol and levosalbutamol-related adverse events, which might provide additional information to guide their use in clinical practice.

Keywords: Salbutamol, Levosalbutamol, Safety profile, Drug-related ADRs